Better Health for All

United Therapeutics' core business is dedicated to developing innovative products for chronic and life-threatening diseases like pulmonary hypertension, with its entire business focused on health improvement, indicating exceptional health benefits.

The company demonstrates perfect risk transparency by providing comprehensive safety information, including warnings, precautions, contraindications, and links to full FDA-approved prescribing information for its products. It supports the healthcare workforce through collaborations with specialty pharmacies, offering nurse visits, ongoing assistance, and 24-hour phone support. The company also provides patient education programs, including Patient Navigators and educational materials. During public health emergencies, United Therapeutics has funded World Central Kitchen to provide meals for victims of natural disasters and conflict in Ukraine, Israel, and Gaza. The company sponsors organizations advancing diversity, equity, and inclusion and funds organizations serving marginalized communities. An expanded access program for investigational drugs is available, with requests acknowledged within 7 business days.

Fair Money & Economic Opportunity

United Therapeutics Corporation is a biotechnology company focused on the development, manufacturing, and sale of pharmaceutical products. The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer consumer credit products or financial services.

While the company provides patient support programs, including co-pay assistance for medications, these are not financial services in the context of the 'Fair Money & Economic Opportunity' value. Therefore, all KPIs related to financial services are not applicable to United Therapeutics Corporation's operations.

Fair Pay & Worker Respect

United Therapeutics reported a CEO to median employee pay ratio of 109:1 in 2024.

The company's OSHA recordable incident rate was 1.2 per 100 full-time workers in 2023, which is below the pharmaceutical preparation manufacturing industry average of 1.6. Over 90% of employees responding to the Great Places to Work survey from 2018-2024 consider United Therapeutics a Great Place to Work. The voluntary turnover rate was 5% in 2023, significantly lower than the 13.5% industry average.

Honest & Fair Business

United Therapeutics Corporation has a whistleblower policy that includes a 24/7/365 anonymous phone line (EthicsPoint) and other reporting channels, along with a policy against retaliation for good-faith reporting.

Reports of violations are investigated or addressed promptly. However, there is no evidence provided regarding independent investigation processes for these reports. The company also maintains a zero-tolerance policy regarding bribery and corruption, prohibiting payments or gifts that would violate anti-bribery laws, and states compliance with U.S. and international anti-bribery laws. It directs employees to oversee third parties to monitor their compliance with policies and applicable laws, including the Global Anti-Bribery and Anti-Corruption Policy. However, the articles do not provide evidence of training frequency or effectiveness metrics for the anti-corruption program.

Kind to Animals

United Therapeutics has an Animal Welfare Policy that supports legitimate and humane scientific research using animals, operating with ethical and scientific standards, and in strict compliance with federal, state, and local regulations.

The policy acknowledges that U.S. federal laws require certain animal research studies. The company is actively involved in xenotransplantation, using genetically modified pigs as organ donors for humans. Its subsidiary, Revivicor, maintains a research farm with approximately 300 pigs for this purpose. As of July 31, 2024, 11 xenotransplantation procedures using United Therapeutics' organs have been performed in living and brain-dead human recipients. The clinical-scale designated pathogen-free facility, opened in February 2024, has an initial capacity of up to 125 organs per year. The FDA approved the GalSafe pig line, developed by Revivicor, for use as human food or as a potential source for biomedical purposes in 2020. The company invested $481 million in R&D in 2024 and $408 million in 2023, but no specific percentage of this budget is stated as being allocated to animal-free technologies. United Therapeutics collaborates with academic medical centers on xenotransplantation research and is a member of the International Xenotransplantation Association. The company rechartered as a public benefit corporation in 2021 and engages in public policy discussions related to xenotransplantation, including patient education and increasing access to kidney transplants, and adheres to the Animal Welfare Act.

No War, No Weapons

United Therapeutics has a Conflict Minerals Policy, version 1.0, effective April 24, 2024, which applies to all employees, directors, shareholders, and suppliers.

This policy outlines a risk-based approach for identifying and mitigating conflict mineral risks in the supply chain, specifically for tantalum, tin, tungsten, and gold (3TG minerals). The company commits to annual reporting on its mineral sourcing practices. A conflict minerals disclosure states that no Conflict Minerals from Covered Countries were found in their products.

Planet-Friendly Business

Approximately 26% of United Therapeutics' total square footage is LEED certified.

The company has an outstanding track record in meeting wastewater discharge standards, consistently earning water stewardship awards, and received the Washington Suburban Sanitary Commission Gold Level award for consistent compliance in 2023 and 2024. A packaging redesign for one product resulted in up to 73% less packaging material, up to 65% less plastic, and a decrease in estimated greenhouse gas over previous packaging by up to almost 80%. The company is completing work in 2024 to better align with TCFD recommendations, plans to disclose how they are examining and preparing for climate risks in 2025, and is preparing a TCFD report for publication. They analyzed potential physical risks from climate change across owned and leased operations in 2023 and 2024, and are developing an initial climate risk and opportunity assessment by the end of 2025. The company maintains almost 7-MW of onsite solar capacity. In 2024, it diverted more than 187,194 pounds of food waste from landfill through composting programs at two headquarters locations. The company aims for new construction sites to be net-zero energy when feasible, and aspires to integrate site net zero energy and site net zero embodied carbon principles into new construction where feasible. An apiary was installed by Bee Downtown in the pollinator field surrounding the 4-MW solar array in RTP.

Respect for Cultures & Communities

United Therapeutics Corporation provided approximately $6.1 million in grants, sponsorships, and financial donations to just under 140 organizations in 2024, which includes local community groups.

The company's PAH Initiative team has translated materials into multiple languages to support underserved communities. The company's business model, focused on biotechnology and pharmaceutical products, does not involve operations where Free, Prior and Informed Consent (FPIC) processes are applicable. While the Thurgood Marshall College Fund, a recipient of donations, supports institutions with cultural heritage, the percentage of total revenue donated specifically to cultural heritage organizations is not provided, nor is the total annual revenue for 2024 to calculate this percentage.

Zero Waste & Sustainable Products

United Therapeutics has implemented several waste reduction initiatives, including composting programs at two headquarters locations, which diverted over 187,194 pounds of food waste from landfill in 2024.

The company also focuses on waste minimization through container reuse, landfill-free disposal where feasible, and waste-to-energy treatment. A packaging redesign project for Tyvaso, concluded in 2024, resulted in up to 65% less plastic and up to 73% less packaging material compared to previous formats. This redesign also led to a 73% reduction in material use and a 70% volume reduction for the Refill Supply Kit (RSK), and a 36% material reduction and 54% volume reduction for the Patient Starter Kit (PSK). The company manages regulated hazardous waste through compliant container storage and labeling, careful packaging, maintaining accurate waste profiles, and shipping to audited storage and treatment facilities. A process development initiative, pending FDA approval, aims to eliminate certain hazardous reagents and reduce solvent use for one therapy. United Therapeutics participates in the Pharmaceutical Product Stewardship Work Group (PPSWG) MyOldMeds program, which provides patients with an easy, safe, and sustainable way to dispose of unwanted, unused, or expired medicines.